Current and next generation influenza vaccines: Formulation and production strategies

被引:214
|
作者
Soema, Peter C. [1 ,2 ]
Kompier, Ronald [1 ,3 ]
Amorij, Jean-Pierre [1 ]
Kersten, Gideon F. A. [1 ,2 ]
机构
[1] Intravacc Inst Translat Vaccinol, Bilthoven, Netherlands
[2] Leiden Univ, Div Drug Delivery & Technol, Leiden Acad Ctr Drug Res, NL-2300 RA Leiden, Netherlands
[3] FluConsult, Noordwijk, Netherlands
关键词
Influenza vaccines; Vaccine formulation; Vaccine production; Novel influenza vaccines; Influenza vaccine limitations; Universal influenza vaccine; HUMORAL IMMUNE-RESPONSES; CROSS-REACTIVE ANTIBODIES; SYNTHETIC PEPTIDE VACCINE; VIRUS-LIKE PARTICLE; IN-WATER EMULSION; A VIRUS; SEASONAL INFLUENZA; DOUBLE-BLIND; H5N1; VACCINE; PROTECTIVE EFFICACY;
D O I
10.1016/j.ejpb.2015.05.023
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Vaccination is the most effective method to prevent influenza infection. However, current influenza vaccines have several limitations. Relatively long production times, limited vaccine capacity, moderate efficacy in certain populations and lack of cross-reactivity are important issues that need to be addressed. We give an overview of the current status and novel developments in the landscape of influenza vaccines from an interdisciplinary point of view. The feasibility of novel vaccine concepts not only depends on immunological or clinical outcomes, but also depends on biotechnological aspects, such as formulation and production methods, which are frequently overlooked. Furthermore, the next generation of influenza vaccines is addressed, which hopefully will bring cross-reactive influenza vaccines. These developments indicate that an exciting future lies ahead in the influenza vaccine field. (C) 2015 The Authors. Published by Elsevier B.V.
引用
收藏
页码:251 / 263
页数:13
相关论文
共 50 条
  • [1] Next-Generation Influenza Vaccines
    Kanekiyo, Masaru
    Graham, Barney S.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2021, 11 (08):
  • [2] Overcoming formulation challenges for the next generation of vaccines
    Berkland, Cory
    Middaugh, C. Russell
    EXPERT OPINION ON DRUG DELIVERY, 2016, 13 (11) : 1501 - 1502
  • [3] Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication
    Kumar, Prashant
    Bird, Christopher
    Holland, David
    Joshi, Sangeeta B.
    Volkin, David B.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 18 (07)
  • [4] Next Generation Influenza Vaccines: Looking into the Crystal Ball
    Guzman, Carlos Alberto
    VACCINES, 2020, 8 (03)
  • [5] The Next Generation of Influenza Vaccines: Towards a Universal Solution
    McMillan, Christopher L. D.
    Young, Paul R.
    Watterson, Daniel
    Chappell, Keith J.
    VACCINES, 2021, 9 (01) : 1 - 20
  • [6] Next-generation influenza vaccines: opportunities and challenges
    Wei, Chih-Jen
    Crank, Michelle C.
    Shiver, John
    Graham, Barney S.
    Mascola, John R.
    Nabel, Gary J.
    NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (04) : 239 - 252
  • [7] Next-generation influenza vaccines: opportunities and challenges
    Chih-Jen Wei
    Michelle C. Crank
    John Shiver
    Barney S. Graham
    John R. Mascola
    Gary J. Nabel
    Nature Reviews Drug Discovery, 2020, 19 : 239 - 252
  • [8] Epidemiological Studies to Support the Development of Next Generation Influenza Vaccines
    Petrie, Joshua G.
    Gordon, Aubree
    VACCINES, 2018, 6 (02)
  • [9] Next-generation influenza vaccines based on mRNA technology
    Isakova-Sivak, Irina
    Rudenko, Larisa
    LANCET INFECTIOUS DISEASES, 2025, 25 (01): : 2 - 3
  • [10] Current and next-generation bluetongue vaccines: Requirements, strategies, and prospects for different field situations
    Feenstra, Femke
    van Rijn, Piet A.
    CRITICAL REVIEWS IN MICROBIOLOGY, 2017, 43 (02) : 142 - 155